We provide real-time and in-depth analysis of healthcare legislation, trends among payors and healthcare stakeholders, and policies that originate from healthcare agencies (CMS, FTC, FDA), think tanks and other bodies (MedPAC, BPC, AEI, Brookings) and Capitol Hill (e.g., ARPA-H, Cures, MDUFA).
We also preview, review and analyze Supreme Court and lower court case proceedings that are relevant to our healthcare clients.
For example, our clients use Capitol Street to piece together Hospital Inpatient (IPPS), Outpatient (OPPS) DRG, APC and NTAP Policies, along with the general acute care hospital spending environment. We also assess Budget, Pandemic and Bioterror Funding bills, as they may impact medtech companies via additional funding mechanisms. Precision medicine policies allow the right medicine to be delivered to the right person at the right time; we monitor sequencing initiatives such as NIH’s All of Us. We also geek out on the newest developments in medical technology e.g., liquid biopsy & synthetic biology, to name a few. We look at how private payers and expanding government programs — such as Medicaid and ACA expansions — impact medical technologies, as well as keep a finger on the pulse as to how FDA is classifying and regulating digital technologies, lab developed tests. Sometimes surprise policies — like labor input policies — will drastically swing payment rates for surgical technologies in the physician office: We highlight those policies, as well as others that are likely to be finalized, delayed, phased-in, or scrapped, as well as business impact.